BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35307815)

  • 1. A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
    Joung RH; Nelson H; Mullett TW; Kurtzman SH; Shafir S; Harris JB; Yao KA; Brajcich BC; Bilimoria KY; Cance WG
    Cancer; 2022 Jun; 128(11):2119-2125. PubMed ID: 35307815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening.
    Joung RH; Mullett TW; Kurtzman SH; Shafir S; Harris JB; Yao KA; Bilimoria KY; Cance WG; Nelson H;
    JAMA Netw Open; 2022 Nov; 5(11):e2242354. PubMed ID: 36383381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea.
    Park H; Seo SH; Park JH; Yoo SH; Keam B; Shin A
    Epidemiol Health; 2022; 44():e2022053. PubMed ID: 35760396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese cancer screening programs during the COVID-19 pandemic: Changes in participation between 2017-2020.
    Machii R; Takahashi H
    Cancer Epidemiol; 2023 Feb; 82():102313. PubMed ID: 36508964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based survey of self-reported delays in breast, cervical, colorectal and lung cancer screening.
    Gunn CM; Berrian K; Weiss JE; Tosteson AAN; Hasson RM; Di Florio-Alexander R; Peacock JL; Rees JR
    Prev Med; 2023 Oct; 175():107649. PubMed ID: 37517458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Screening Disparities Before and After the COVID-19 Pandemic.
    Lofters AK; Wu F; Frymire E; Kiran T; Vahabi M; Green ME; Glazier RH
    JAMA Netw Open; 2023 Nov; 6(11):e2343796. PubMed ID: 37983033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic.
    Chen RC; Haynes K; Du S; Barron J; Katz AJ
    JAMA Oncol; 2021 Jun; 7(6):878-884. PubMed ID: 33914015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global Association of COVID-19 Pandemic Measures With Cancer Screening: A Systematic Review and Meta-analysis.
    Teglia F; Angelini M; Astolfi L; Casolari G; Boffetta P
    JAMA Oncol; 2022 Sep; 8(9):1287-1293. PubMed ID: 35797056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and inequities in colorectal and cervical cancer screening and diagnosis in Washington State.
    Amram O; Amiri S; Robison J; Pflugeisen CM; Monsivais P
    Cancer Med; 2022 Aug; 11(15):2990-2998. PubMed ID: 35304835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding COVID-19 impact on cervical, breast, and colorectal cancer screening among federally qualified healthcare centers participating in "Back on track with screening" quality improvement projects.
    Fisher-Borne M; Isher-Witt J; Comstock S; Perkins RB
    Prev Med; 2021 Oct; 151():106681. PubMed ID: 34217422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National Breast, Cervical, and Colorectal Cancer Screening Use in Federally Qualified Health Centers.
    Amboree TL; Montealegre JR; Parker SL; Garg A; Damgacioglu H; Schmeler KM; Chiao EY; Hill EG; Sonawane K; Deshmukh AA; Adsul P
    JAMA Intern Med; 2024 Jun; 184(6):671-679. PubMed ID: 38683574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium.
    Barlow WE; Beaber EF; Geller BM; Kamineni A; Zheng Y; Haas JS; Chao CR; Rutter CM; Zauber AG; Sprague BL; Halm EA; Weaver DL; Chubak J; Doria-Rose VP; Kobrin S; Onega T; Quinn VP; Schapira MM; Tosteson ANA; Corley DA; Skinner CS; Schnall MD; Armstrong K; Wheeler CM; Silverberg MJ; Balasubramanian BA; Doubeni CA; McLerran D; Tiro JA
    J Natl Cancer Inst; 2020 Mar; 112(3):238-246. PubMed ID: 31292633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US women screen at low rates for both cervical and colorectal cancers than a single cancer: a cross-sectional population-based observational study.
    Harper DM; Plegue M; Jimbo M; Sheinfeld Gorin S; Sen A
    Elife; 2022 Jun; 11():. PubMed ID: 35762572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia.
    Nickson C; Smith MA; Feletto E; Velentzis LS; Broun K; Deij S; Grogan P; Hall M; He E; St John DJ; Lew JB; Procopio P; Simms KT; Worthington J; Mann GB; Canfell K
    Elife; 2023 Apr; 12():. PubMed ID: 37022767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic Examination of COVID-19 Test Percent Positivity and Proportional Change in Cancer Screening Volume, National Breast and Cervical Cancer Early Detection Program.
    Bermudez Y; Scott LC; Beckman M; DeGroff A; Kenney K; Sun J; Rockwell T; Helsel W; Kammerer W; Sheu A; Miller J; Richardson LC
    Prev Chronic Dis; 2022 Sep; 19():E59. PubMed ID: 36108291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in cancer screening before and during COVID-19: findings from the Korean National Cancer Screening Survey 2019 and 2020.
    Trinh TTK; Lee YY; Suh M; Jun JK; Choi KS
    Epidemiol Health; 2022; 44():e2022051. PubMed ID: 35638224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs.
    Zhang L; Mosquera I; Lucas E; Rol ML; Carvalho AL; Basu P;
    Nat Med; 2023 May; 29(5):1135-1145. PubMed ID: 37106168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.
    Taksler GB; Peterse EFP; Willems I; Ten Haaf K; Jansen EEL; de Kok IMCM; van Ravesteyn NT; de Koning HJ; Lansdorp-Vogelaar I
    JAMA Oncol; 2021 Jun; 7(6):885-894. PubMed ID: 33914025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer screening participation in schizophrenic outpatients and the influence of their functional disability on the screening rate: A cross-sectional study in Japan.
    Fujiwara M; Inagaki M; Nakaya N; Fujimori M; Higuchi Y; Hayashibara C; So R; Kakeda K; Kodama M; Uchitomi Y; Yamada N
    Psychiatry Clin Neurosci; 2017 Dec; 71(12):813-825. PubMed ID: 28875514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oncological organized screening programmes in the COVID-19 era: an Italian survey on accrued delays, reboot velocity, and diagnostic delay estimates].
    Mantellini P; Battisti F; Armaroli P; Giubilato P; Ventura L; Zorzi M; Battagello J; Sassoli de Bianchi P; Senore C; Zappa M
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):344-352. PubMed ID: 33412828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.